"Not So Different" Episode 3: Pricing

Podcast

Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA, who joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.

In our first 2 episodes, we brought you multi-stakeholder discussions of biosimilar interchangeability and nonmedical switching.

Today, we’re changing gears and bringing you a perspective from the business side of biosimilars. Our guest on this episode of "Not So Different" is Jim Van Lieshout, MBA.

Van Lieshout is a consultant with 37 years of experience in developing market access strategies for pharmaceutical companies. Most recently, Van Lieshout worked in the Apotex family of companies, as vice president of trade and industry relations for Apobiologix. He joined us by phone from Colorado to discuss the many considerations that biosimilar developers must take into account when they determine how to price their products to compete in the marketplace.

Related Videos
Here are some of our most-listened-to 2020 "Not So Different" podcasts.
Related Content
© 2024 MJH Life Sciences

All rights reserved.